Johnson & Johnson’s problems over its antipsychotic drug Risperdal continue. On April 11 a Little Rock state court judge ordered the company to pay the state of Arkansas $1.2 billion. The order followed a jury verdict against J&J that found that Johnson & Johnson and subsidiary Janssen Pharmaceuticals Inc. had defrauded the state’s Medicaid program when it hid the risks associated with Risperdal.
J&J’s lead lawyer was Thomas Campion of Drinker Biddle & Reath; the company has already announced an intention to appeal.
